What Is a Serious Adverse Event in Research, and How Is It Different From an Adverse Event?

When does an adverse event become a serious adverse event?

A participant reports severe nausea after a research intervention but recovers at home. Another participant experiences a medical event described as moderate but requires inpatient hospitalization. Which one is the serious adverse event?

The answer is not necessarily the participant with the more intense symptoms. In research safety, seriousness and severity describe different things. Seriousness is generally determined by specified outcomes or consequences of an adverse event, while severity describes its intensity.

This distinction matters because classifying an event as a serious adverse event, commonly abbreviated SAE, may trigger additional assessment, documentation, notification, and reporting requirements. Those requirements depend on the regulatory framework and study rather than on the word “serious” alone.

A serious adverse event is a specific subset of adverse events

What makes an adverse event serious?

The difference between an AE and an SAE is primarily the outcome

An adverse event is broadly an unfavorable medical occurrence meeting the definition applicable to the study. A serious adverse event is a narrower category within that larger group.

ICH E6(R3) identifies an SAE as an unfavorable medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongs existing hospitalization, results in persistent or significant disability or incapacity, or is a congenital anomaly or birth defect. Important medical events that jeopardize the participant or require intervention to prevent a serious outcome should generally also be considered serious.

Death is a seriousness criterion

An adverse event that results in death meets a standard seriousness criterion. This does not mean that every death occurring while someone is enrolled in research was caused by the study. A participant may die from progression of an underlying disease or from another cause unrelated to participation.

OHRP, for example, describes the death of a participant in an observational cancer registry from progression of cancer as an adverse event unrelated to participation in the research. It also gives the example of a participant in the same type of registry being struck by a car, an event unrelated both to the research and to the underlying disease.

Seriousness therefore tells you something about the event's outcome. It does not settle whether the research caused or contributed to it.

“Life-threatening” means immediate risk of death

The term life-threatening has a narrower meaning than it sometimes has in ordinary conversation. FDA defines a life-threatening adverse event as one that, in the view of the investigator or sponsor, places the participant at immediate risk of death. It does not include an event that hypothetically could have caused death if it had been more severe.

ICH E2A makes the same distinction. The question is what actually happened to the participant during the event, not what might have happened in a more extreme version of it.

Hospitalization can make an event serious

An AE requiring inpatient hospitalization or prolongation of an existing hospitalization meets a standard SAE criterion. FDA further distinguishes inpatient admission from an emergency-room visit that does not result in admission. An emergency-room visit alone is not automatically equivalent to hospitalization for this criterion, although the event may still qualify as serious under another criterion.

This is why researchers should document what actually happened rather than merely recording that a participant “went to hospital.” Was the participant evaluated and discharged from the emergency department? Was the participant admitted? Did an event prolong an existing hospital stay? Those details can affect the seriousness assessment.

Significant disability or incapacity can qualify

An event may also be serious when it results in persistent or significant disability or incapacity. FDA describes this criterion in terms of persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions.

The key issue is therefore not simply whether a participant found an event inconvenient or temporarily uncomfortable. The applicable definition and clinical assessment should determine whether the resulting impairment reaches the seriousness threshold.

Congenital anomalies and birth defects are seriousness criteria

A congenital anomaly or birth defect is another standard criterion appearing in FDA, OHRP, and ICH definitions of serious adverse events.

An event can be serious without hospitalization or immediate danger of death

The formal criteria also contain an important medical-judgment provision. Some medically important events may not cause death, immediate life-threatening danger, hospitalization, disability, or a congenital anomaly, yet may jeopardize the participant or require medical or surgical intervention to prevent one of those outcomes.

ICH E2A gives examples such as intensive treatment for allergic bronchospasm, certain blood disorders, convulsions that do not result in hospitalization, and development of drug dependency or abuse.

Serious and severe are not synonyms

This is one of the most important distinctions in adverse-event terminology.

ICH E2A explicitly warns that “serious” and “severe” are not synonymous. Its guidance uses a severe headache to illustrate how an event can be intense without necessarily being medically serious in the regulatory sense. Seriousness, rather than severity, is used in determining certain regulatory reporting obligations.

Serious does not mean related, and serious does not mean unexpected

An SAE can be serious and unrelated to the research. It can also be serious but expected based on existing information about the intervention or study population.

Think of these as separate questions: What happened? Was the outcome serious? Was it expected? Could the research have caused or contributed to it? Does it meet a particular reporting requirement?

That last question is especially important. SAE classification alone does not establish one universal reporting pathway for every study, sponsor, IRB or REC, or jurisdiction. The applicable adverse-event reporting requirements must still be checked.

Severe symptoms and serious outcomes can point in different directions

The example illustrates why simply asking, “How bad was it?” is insufficient. SAE classification asks whether defined seriousness criteria were met.

Common mistakes when classifying serious adverse events

Assess seriousness separately from everything else

When an AE occurs, avoid using one label to answer several different safety questions. First establish what happened. Then assess seriousness according to the criteria governing the study.

Once seriousness has been assessed, do not stop there. Determine relatedness, expectedness, required participant care, documentation, follow-up, and reporting under the protocol and applicable requirements.

Before classifying an event as serious or non-serious

Frequently asked questions about serious adverse events

Seriousness is about defined outcomes, not simply intensity

How to Cite This Guide

This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.